Anthony Fung REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida ANTHONY FUNG, University of British Columbia, Vanc
Anthony FungREFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, FloridaANTHONY FUNG, University of British Columbia, VancouverBrief courses of antiplatelet therapy with the glycoprotein 2b 3a inhibitor are just as effective as longer infusions for patients receiving non-emergency percutaneous intervention. So saidAnthony Fungat the first session of Late breaking Clinical Trials held at the American Heart Association’s annual meeting in Orlando. He talked with Peter Goodwin about his findings.
Related Episodes
Audio Journal of Oncology Volume 16 Number 9
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod
Audio Journal of Oncology Volume 16 Number 8
Scientific Editors: George Canellos, Pat Price, Gordon McVie, Gianni Bonadonna In this edition: Bevacizumab and Survival in Metastatic Breast Cancer Source: N Engl J Med 357:26 George Canellos, Dana-F
Heart Failure Drug Prevents Renal Damage?
Barry Massie Barry Massie, San Francisco VA Medical Center COMMENT: Aaron Kugelmass, Henry Ford Hospital, Detroit The adenosine A1-receptor antagonist rolofylline appears to prevent renal impairment a